Colorectal Cancer :: Xeloda meets primary endpoint in multinational Phase III advanced colorectal cancer study
Roche announced today that a large, international Phase III study (NO16967) of 627 previously treated patients with advanced colorectal cancer met its primary endpoint of progression-free survival.